Reactions of connective tissue to amalgam, intermediate restorative material, mineral trioxide aggregate, and mineral trioxide aggregate mixed with chlorhexidine.
The aim of this study was to histopathologically examine the biocompatibility of the high-copper amalgam, intermediate restorative material (IRM), mineral trioxide aggregate (MTA), and MTA mixed with chlorhexidine (CHX). This study was conducted to observe the rat subcutaneous connective tissue reaction to the implanted tubes filled with amalgam, IRM, MTA, and MTA mixed with CHX. The animals were sacrificed 15, 30, and 60 days after the implantation procedure. The implant sites were excised and prepared for histological evaluation. Sections of 5 to 6 microm thickness were cut by a microtome and stained with hemotoxylin eosin and examined under a light microscope. The inflammatory reactions were categorized as weak (none or few inflammatory cells < or =25 cells), moderate (>25 cells), and severe (a lot of inflammatory cells not to be counted, giant cells, and granulation tissue). Thickness of fibrous capsules measured five different areas by the digital imaging and the mean values were scored. Amalgam, IRM, and MTA mixed with CHX caused a weak inflammatory response on days 15, 30, and 60. MTA provoked an initial severe inflammatory response that subsided at the 30 and 60 day study period. A clear fibrous capsule was observed beginning from the 15 days in all of the groups. Within the limits of this study, amalgam, IRM, MTA, and MTA mixed with CHX materials were surrounded by fibrous connective tissue indicated that they were well tolerated by the tissues, therefore, MTA/CHX seemed to be biocompatible.
Sumer
Mahmut
M
Department of Oral Surgery, Faculty of Veterinary, University of Ondokuz Mayis, Samsun, Turkey. msumer1970@yahoo.com
Muglali
Mehtap
M
Bodrumlu
Emre
E
Guvenc
Tolga
T
D017607:Aluminum Compounds / Q000494:pharmacology*; D000818:Animals; D000891:Anti-Infective Agents, Local / Q000494:pharmacology*; D001672:Biocompatible Materials / Q000494:pharmacology; D017610:Calcium Compounds / Q000494:pharmacology*; D002710:Chlorhexidine / Q000494:pharmacology*; D004396:Coloring Agents; D003238:Connective Tissue / Q000187:drug effects / Q000473:pathology; D003300:Copper / Q000494:pharmacology; D003723:Dental Amalgam / Q000494:pharmacology*; D004338:Drug Combinations; D005355:Fibrosis; D015726:Giant Cells / Q000473:pathology; D006097:Granulation Tissue / Q000473:pathology; D020007:Implants, Experimental; D007249:Inflammation; D008297:Male; D008422:Materials Testing; D008768:Methylmethacrylates / Q000494:pharmacology*; D008867:Microtomy; D010087:Oxides / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012387:Root Canal Filling Materials / Q000494:pharmacology*; D017640:Silicates / Q000494:pharmacology*; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D013997:Time Factors; D015035:Zinc Oxide-Eugenol Cement / Q000494:pharmacology*
D017607:Aluminum Compounds; D000891:Anti-Infective Agents, Local; D001672:Biocompatible Materials; D017610:Calcium Compounds; D004396:Coloring Agents; D004338:Drug Combinations; D008768:Methylmethacrylates; D010087:Oxides; D012387:Root Canal Filling Materials; D017640:Silicates; D015035:Zinc Oxide-Eugenol Cement; C086631:mineral trioxide aggregate; C031667:IRM cement; D003300:Copper; D003723:Dental Amalgam; D002710:Chlorhexidine